Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:00 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1245

Shown on this page

Current sort

Live official records

Conditions: Single Ventricle Heart Disease
Interventions: Udenafil, Placebo; Drug
Lead sponsor: Mezzion Pharma Co. Ltd; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab soravtansine, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Tucson, Arizona • Fresno, California • Fullerton, California + 30 more

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions: Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 55
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 42 more

Conditions: Alopecia Areata
Interventions: CTP-543; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more

Conditions: Ventricular Tachycardia
Interventions: Intrinsic Antitachycardia Pacing (iATP) Therapy; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 51
States / cities: Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more

Conditions: Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
Interventions: IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort; Combination Product
Lead sponsor: Medtronic; Industry
Eligibility: 21 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 20
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 17 more

Conditions: Peripheral Arterial Disease
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-small Cell Lung Cancer
Interventions: Erlotinib, Hydroxychloroquine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 4
States / cities: Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Interventions: asciminib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more

Conditions: PTSD, Alcohol Use Disorder
Interventions: Brexanolone; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 4 Months and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 52
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more

Conditions: Heart Failure
Interventions: Ertugliflozin, Metolazone, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

IN.PACT™ AV Access Post-Approval Study (PAS002)

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

Ertugliflozin in Chronic Heart Failure

About this Yale institution page